

## RECORDATI: PUBLICATION OF THE LIST OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS OF THE COMPANY

Milan, 8<sup>th</sup> April 2020 – Pursuant to art. 144-octies, paragraph 1 of Consob’s Regulation 11971/1999 (“**Issuers’ Regulations**”) and with reference to the Ordinary General Meeting of the Shareholders to be held on 29<sup>th</sup> April 2020 in a single call, RECORDATI S.p.A. informs that the following lists for the appointment of the Statutory Auditors are available to the public on the "1info" storage mechanism ([www.1info.it](http://www.1info.it)) and on the Company’s website ([www.recordati.it](http://www.recordati.it) - section Investors - Shareholders Meetings):

- the list filed by the majority shareholder, Fimei S.p.A., which owns 51.82% of RECORDATI S.p.A.’s share capital (List No. 1);
- the list filed by a group of asset management companies and institutional investors which collectively own about 0.79509% of RECORDATI S.p.A.’s share capital (List No. 2).

Please note that the above mentioned lists are available jointly with the relevant documentation requested by law and by the Company’s By-laws.

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

### Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

### Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

### RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale

VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v.  
REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150  
CODICE FISCALE/P. IVA 00748210150  
R.E.A. MILANO 401832

Società Soggetta all'attività di Direzione e Coordinamento di Rossini Luxembourg S.à.r.l